Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$12.17
▲ $0.09 (+0.7%)
Market data updated: 09/20 06:38 AM
News analyzed: 09/20/2026
Market Cap
$415.81M
Day Range
$11.63 - $12.99
52-Week Range
$8.75 - $17.82
Beta
—
Next Earnings
—
Support
$11.21
Resistance
$16.50
AGMB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-16.9% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 1/11 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Relative strength vs. S&P 500
+8.8% over the last 3 months relative to the index
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 10.4% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Agomab Therapeutics (AGMB) exhibits a strong technical foundation, supported by a **90/100 score** driven by clear bullish momentum indicators. The stock price remains above both its **50-day and 200-day moving averages**, reinforcing its uptrend, while a **positive MACD histogram** and **RSI of 62.6** (indicating healthy upward momentum) further validate its strength. However, the **%K at 70.9** suggests a near-neutral stochastic reading, which could signal potential overbought conditions if not monitored. The **news category (62/100)** reflects mixed analyst sentiment, with some bullish coverage (e.g., Piper Sandler’s Overweight rating) but no major positive catalysts. The **risk score (42/100)** is constrained by a **7.1% ATR**, indicating moderate volatility relative to price, which may pose execution challenges for traders. Overall, the stock’s technical robustness and selective analyst optimism are balanced by inherent volatility risks and a lack of transformative news drivers.
The stock price is firmly above both its 50-day and 200-day moving averages, with a positive MACD histogram and RSI of 62.6 indicating strong upward momentum. The stochastic %K at 70.9 suggests a neutral reading, potentially signaling overbought conditions.
Strong technicals suggest sustained bullish momentum, but stochastic readings may warrant caution against overvaluation.
Analyst coverage is mixed, with some bullish initiations (e.g., Piper Sandler’s Overweight rating) but no major positive earnings or clinical updates. Most news items are neutral or speculative.
Limited high-impact news weakens the stock’s fundamental catalyst, relying more on technical momentum than substantive corporate developments.
The ATR stands at **7.1% of the stock price**, indicating moderate volatility that could lead to wider bid-ask spreads or price whipsaws.
Higher volatility increases execution risk and may deter conservative investors or institutional players seeking stability.
StockIQ conclusion
Agomab Therapeutics (AGMB) demonstrates **strong technical momentum** with price above key moving averages and positive momentum oscillators, supported by selective analyst optimism. However, its **moderate volatility (7.1% ATR)** and **lack of high-impact news** introduce execution and fundamental risks. The stock’s performance hinges on maintaining its uptrend while avoiding overbought conditions, with potential upside tied to future clinical or regulatory developments. Without transformative catalysts, the current strength remains speculative and dependent on technical trends.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/11/202640
This Week
74
7D Ago
↓ -34
Weakening
Technical
31
7D Ago: 85
↓ -54
News
62
7D Ago: 62
→ 0
Risk
42
7D Ago: 42
→ 0
Biggest Declines
📊 Score History
40
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
5d ago · $13.08
Evidence: Narrative Gap moved from 14 to -11 day-over-day
What happened after
Still awaiting outcome
14d ago · $15.78
Evidence: Narrative Gap moved from -9 to 16 day-over-day
What happened after
14d ago · $15.78
Evidence: FOMO score jumped from 11 to 60 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
40 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of September 10, 2026
Then
74
$14.96
Now
40
$12.17
What happened since
Signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
31
Risk
42
Sentiment
62
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of AgomAb Therapeutics NV has focused on its positive analyst reception and strategic developments. Multiple firms, including Piper Sandler and Cantor Fitzgerald, initiated **overweight ratings** with price targets of $60, signaling bullish optimism. The company also announced proposed board appointments of Marino Garcia and Dr. Naimish Patel, pending shareholder approval. Additionally, AgomAb reported **half-year financial results**, highlighted regulatory alignment with the FDA for its **NOV-ERA Phase 2b study** in fibrostenosing Crohn’s disease, and anticipated upcoming data from long-term extension studies and a Phase 1b IPF trial.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about AgomAb Therapeutics NV - ADRs representing one common share.. News trend score: 62. Reason: 6 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
19
🎯 Conviction (vs. Emotion)
50
Psychology
23
Fundamentals
—
Technical
31
Valuation
—
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+11%
Market Narrative
37
Fundamental Reality
50
Narrative Gap
-13
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **FOMO** dominates, fueled by strong momentum and elevated volume, while euphoria lingers due to the stock’s significant outperformance relative to its 200-day baseline. The narrative-reality gap (12 points) implies traders may be overestimating the stock’s fundamentals or growth potential. The key open question is whether the momentum will sustain or if traders will pivot to euphoria-driven overvaluation. Anchoring near resistance could act as a psychological barrier, but the lack of panic selling signals no immediate panic reversal.
Updated: 09/09/2026, 02:59 PM
What could change this?
👥 What the crowd believes
"Piper Sandler initiates coverage on AgomAb Therapeutics with Overweight rating and $60 price target"
"Proposed appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors"
"Regulatory alignment with U.S. FDA on key elements of NOV-ERA Phase 2b study design"
"Topline Data from Open-Label Long-term Extension Study expected in coming months"
🧠 Market Brain events driving this
📈 10D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 92/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The methodologies here split sharply between cautious skepticism and outright rejection of AGMB, with only a few approaches showing mild curiosity. Jesse Livermore’s near-neutral stance (67) contrasts with the majority—most frameworks like Fisher, Graham, or Lynch (all at 50) flag a lack of sufficient data to apply their core principles, suggesting they’d need more concrete fundamentals to engage. Meanwhile, behavioral and cycle-based thinkers like Marks (45) and Nelson (28) see either overvaluation or a stretched market dynamic, while risk-averse voices like Loeb (26) and Housel (0) outright dismiss it as volatile or capital-threatening. The divide underscores whether AGMB’s speculative appeal (noted by Mackay’s 55) outweighs its structural or cyclical risks—most models default to neutrality or avoidance, but a few lean toward passive caution rather than outright dismissal.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 92
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 89
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 61
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 51
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 24
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 10
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 155 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 7 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 6 positive, 10 neutral, 4 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
Yahoo · 14.9.2026
Yahoo · 11.9.2026
GlobeNewswire · 11.9.2026
GlobeNewswire · 3.9.2026
Benzinga · 25.8.2026
Benzinga · 25.8.2026
MT Newswires · 19.8.2026
Benzinga · 19.8.2026
Benzinga · 19.8.2026
GlobeNewswire · 10.8.2026
Yahoo · 10.8.2026
GlobeNewswire · 6.8.2026
Yahoo · 6.8.2026
Benzinga · 6.8.2026
MT Newswires · 23.7.2026
Benzinga · 23.7.2026
Insider Monkey · 2.7.2026
MT Newswires · 26.6.2026
MT Newswires · 23.6.2026
StockIQ doesn't currently have enough real data to compute a reliable score for AgomAb Therapeutics NV - ADRs representing one common share. (AGMB) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for AGMB specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
AGMB's technical score is 31/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: +8.8% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: ATR: 10.4% of price; Price is below the 50-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for AGMB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
878,372 shares short as of 2026-08-31 · vs. 1,204,962 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
37.5% of trading volume this week was short selling, vs. 49.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology